Tag: Ranger

LINC 2021: Head-to-head trials take centre stage in drug-eluting technology late-breaking...

Data from two head-to-head trials on drug-eluting technologies in femoral artery treatment were presented during a late-breaking session at LINC 2021 (Leipzig Interventional Course;...

Boston Scientific receives FDA approval for the Ranger DCB

Boston Scientific announced it has received US Food and Drug Administration (FDA) approval of the Ranger drug-coated balloon (DCB), developed for the treatment of...

LINC 2020: High- and low-dose paclitaxel-coated balloons exhibit comparable results at...

At the 2020 Leipzig Interventional Course (28–31 January, Leipzig, Germany), Sabine Steiner (University of Leipzig, Leipzig, Germany) presented one-year results of the COMPARE-RTC of...

First data from head-to-head comparison of Ranger and IN.PACT drug-coated balloons...

Early data from the first randomised controlled trial to compare two drug-coated balloons (DCBs) suggest that the primary patency obtained with the Ranger DCB...

Positive results for Boston Scientific Ranger paclitaxel-coated PTA balloon catheter

Positive results from the RANGER SFA trial for Boston Scientific’s Ranger paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter have been presented at the 2017...